21:51 , Aug 15, 2018 |  BC Extra  |  Financial News

Blackstone investing $400M in Chinese company HEC

YiChang HEC Changjiang Pharmaceutical Co. Ltd. (HKSE:1558) said it will sell $400 million in convertible bonds to Blackstone Group, according to a filing on Hong Kong Exchanges and Clearing Ltd. (HKEX). The bonds will bear 3%...
16:27 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Aridis amends IPO

Immunotherapy company Aridis Pharmaceuticals Inc. (San Jose, Calif.) amended its NASDAQ IPO on Aug. 6 and now plans to sell 2 million shares at $13-$15. The offering is being underwritten by Cantor Fitzgerald, Maxim, Laidlaw,...
23:52 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Cell culture studies suggest inhibiting L selectin shedding could help treat latent HIV infection. In L selectin-expressing CD4+ T cells exposed to HIV-1, a tool compound matrix metalloproteinase 1 (MMP1) inhibitor that blocks...
21:08 , Aug 8, 2018 |  BC Extra  |  Politics & Policy

Rep. Collins indicted with insider trading in biotech shares

A grand jury charged Rep. Christopher Collins (R-N.Y.) Wednesday with insider trading in shares of Australian biotech Innate Immunotherapeutics Ltd. (ASX:IIL) by alerting family members of a clinical trial failure before the results were made...
00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
17:53 , Aug 3, 2018 |  BC Week In Review  |  Company News

Kyowa, Ultragenyx sell Priority Review voucher for $80.6M

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) revealed that it and partner Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sold a rare pediatric disease Priority Review voucher during 2Q18 to an undisclosed company for $80.6 million. Ultragenyx spokesperson Danielle Keatley...
17:45 , Jul 31, 2018 |  BC Extra  |  Company News

Kyowa, Ultragenyx sell Priority Review voucher for $80.6M

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) revealed that it and partner Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sold a rare pediatric disease Priority Review voucher during 2Q18 to an undisclosed company for $80.6 million. Ultragenyx spokesperson Danielle Keatley...
18:12 , Jul 27, 2018 |  BC Week In Review  |  Financial News

Neurology company Aquestive raises $67.5M IPO

Aquestive Therapeutics Inc. (NASDAQ:AQST) added $1.05 to $16.05 on July 25 after raising $67.5 million through the sale of 4.5 million shares at $15 in an upsized IPO. Underwriters were BMO Capital Markets, RBC Capital...
17:22 , Jul 27, 2018 |  BC Week In Review  |  Company News

Lee's mulls spin off, HK IPO for China oncology subsidiary

Lee's Pharmaceutical Holdings Ltd. (HKSE:950) said it will consolidate its oncology development pipeline into its China Oncology Focus Ltd. (COF) subsidiary. Lee's CFO Jason Chow told BioCentury that the company expects the reorganization to potentiate...
19:06 , Jul 25, 2018 |  BC Extra  |  Financial News

Aquestive gets modest pop after $67.5M IPO

Aquestive Therapeutics Inc. (NASDAQ:AQST) was up $1.05 to $16.05 in afternoon trading Wednesday after raising $67.5 million through the sale of 4.5 million shares at $15 in an upsized IPO. Underwriters were BMO Capital Markets,...